Effect of Zoledronic Acid on Femoral Bone Loss Following Total Hip Arthroplasty

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In a randomized, double-blind trial, BMD of the operated proximal femur after total hip replacement measured by dual-energy x-ray absorptiometry (DXA) were compared for up to two years in patients receiving IV ZOL 5 mg infusion (n = 27) or placebo (IV saline infusion; n = 24) at two weeks and one year after surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Spokane Joint Replacement Center
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Patients undergoing primary elective total hip replacement

Exclusion Criteria:

• Osteoporosis (BMD ≤-2.5)

• Trauma to the operated femur, hip revisions, femoral dysplasia, trochanteric osteotomy, inflammatory arthritis

• Severe renal impairment

• Use of any medications affecting BMD

• Known sensitivity to bisphosphonates

• Severe dental problems, and pregnancy or being able to conceive and not using reliable birth control methods